Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 597304, 8 pages
http://dx.doi.org/10.1155/2010/597304
Methodology Report

Mitoxantrone Loaded Superparamagnetic Nanoparticles for Drug Targeting: A Versatile and Sensitive Method for Quantification of Drug Enrichment in Rabbit Tissues Using HPLC-UV

Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander University Erlangen-Nürnberg, Section for Experimental Oncology and Nanomedicine (Else Kröner-Fresenius-Foundation-Professorship), Waldstraße 1, 91054 Erlangen, Germany

Received 21 October 2009; Accepted 25 February 2010

Academic Editor: Kazim Husain

Copyright © 2010 Rainer Tietze et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Jurgons, C. Seliger, A. Hilpert, L. Trahms, S. Odenbach, and C. Alexiou, “Drug loaded magnetic nanoparticles for cancer therapy,” Journal of Physics Condensed Matter, vol. 18, no. 38, pp. S2893–S2902, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Alexiou, R. Jurgons, C. Seliger, O. Brunke, H. Iro, and S. Odenbach, “Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting,” Anticancer Research, vol. 27, no. 4, pp. 2019–2022, 2007. View at Google Scholar · View at Scopus
  3. C. Alexiou, W. Arnold, R. J. Klein et al., “Locoregional cancer treatment with magnetic drug targeting,” Cancer Research, vol. 60, no. 23, pp. 6641–6648, 2000. View at Google Scholar · View at Scopus
  4. C. Alexiou, R. Jurgons, C. Seliger, and H. Iro, “Medical applications of magnetic nanoparticles,” Journal of Nanoscience and Nanotechnology, vol. 6, no. 9-10, pp. 2762–2768, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. E. Fox and P. J. Smith, “Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone,” Cancer Research, vol. 50, no. 18, pp. 5813–5818, 1990. View at Google Scholar · View at Scopus
  6. J. Kapuscinski and Z. Darzynkiewicz, “Condensation of nucleic acids by intercalating aromatic cations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 23, pp. 7368–7372, 1984. View at Google Scholar · View at Scopus
  7. D. Faulds, J. A. Balfour, P. Chrisp, and H. D. Langtry, “Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer,” Drugs, vol. 41, no. 3, pp. 401–449, 1991. View at Google Scholar
  8. J. M. Fidler, S. Q. DeJoy, and J. J. Gibbons Jr., “Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function,” Journal of Immunology, vol. 137, no. 2, pp. 727–732, 1986. View at Google Scholar · View at Scopus
  9. J. M. Fidler, S. Q. DeJoy, F. R. Smith III, and J. J. Gibbons Jr., “Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice,” Journal of Immunology, vol. 136, no. 8, pp. 2747–2754, 1986. View at Google Scholar · View at Scopus
  10. F. Wiekhorst, C. Seliger, R. Jurgons et al., “Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting,” Journal of Nanoscience and Nanotechnology, vol. 6, no. 9-10, pp. 3222–3225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Seliger, R. Jurgons, F. Wiekhorst et al., “In vitro investigation of the behaviour of magnetic particles by a circulating artery model,” Journal of Magnetism and Magnetic Materials, vol. 311, no. 1, pp. 358–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Catalin, A. F. Peloux, F. Coloma et al., “Direct determination of mitoxantrone in plasma by high performance liquid chromatography using an automatic precolumn-switching system as sample clean-up procedure,” Biomedical Chromatography, vol. 8, no. 1, pp. 37–41, 1994. View at Google Scholar · View at Scopus
  13. L. Slordal, A. Andersen, and D. J. Warren, “A sensitive and simple high-performance liquid chromatographic method for the determination of mitoxantrone in plasma,” Therapeutic Drug Monitoring, vol. 15, no. 4, pp. 328–333, 1993. View at Google Scholar · View at Scopus
  14. M. J. Priston and G. J. Sewelfe, “Improved LC assay for the determination of mitozantrone in plasma: analytical considerations,” Journal of Pharmaceutical and Biomedical Analysis, vol. 12, no. 9, pp. 1153–1162, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. C. P. Luftensteiner, I. Schwendenwein, B. Paul, H. G. Eichler, and H. Viernstein, “Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats,” Journal of Controlled Release, vol. 57, no. 1, pp. 35–44, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. K. T. Lin, G. E. Rivard, and J.-M. Leclerc, “High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation,” Journal of Chromatography, vol. 465, no. 1, pp. 75–86, 1989. View at Google Scholar · View at Scopus
  17. K. M. Rentsch, R. A. Schwendener, and E. Hanseler, “Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography,” Journal of Chromatography B, vol. 679, no. 1-2, pp. 185–192, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Johnson, A. Ahmad, S. Khan et al., “Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation,” Journal of Chromatography B, vol. 799, no. 1, pp. 149–155, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Lu, S.-B. Xiong, H. Yang, X.-D. Yin, and R.-B. Zhao, “Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: tissue distribution and pharmacodynamics,” International Journal of Pharmaceutics, vol. 307, no. 2, pp. 175–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Hodenius, Polymer- und liposomstabilisierte ferrofluide und ihre funktionalisierung, Ph.D. thesis, Fakultät für Mathematik, Informatik und Naturwissenschaften, 2002.
  21. FDA, “Guidance for Industry Bioanalytical Method Validation,” 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122858.pdf.
  22. J. Wellmitz and M. Gluschke, “Leitlinie zur Methodenvalidierung,” 05-01, 2005.
  23. B. Klejdus, J. Vacek, V. Adam et al., “Determination of isoflavones in soybean food and human urine using liquid chromatography with electrochemical detection,” Journal of Chromatography B, vol. 806, no. 2, pp. 101–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. F. J. Moreno, A. Olano, G. Santa-Maria, and N. Corzo, “Determination of maltodextrins in enteral formulations by three different chromatographic methods,” Chromatographia, vol. 50, no. 11-12, pp. 705–710, 1999. View at Google Scholar · View at Scopus
  25. G. A. Shabir, “Validation of high-performance liquid chromatography methods for pharmaceutical analysis: understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization,” Journal of Chromatography A, vol. 987, no. 1-2, pp. 57–66, 2003. View at Publisher · View at Google Scholar · View at Scopus